Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
Sim M, Hong S, Jung S, et al
doi:10.1097/01.AOG.0000287293.25465.e1 Abodi M, De Cosmi V, Bhowmik A, et al
While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]
Belzung C
US$ 26.46
US$ 28.31
US$ 25.92
US$ 22.22
US$ 29.74
US$ 29.56
